Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model

Tullia C. Bruno, Cristin Rothwell, Joseph F. Grosso, Derese Getnet, Hung Rong Yen, Nicholas M. Durham, George Netto, Drew M. Pardoll, Charles G. Drake

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background: The CD8 T-cell response to prostate and other cancers is often functionally diminished or absent. This may occur via deletion of tumor-specific T cells, through acquisition of an anergic phenotype, or via active suppression mediated by another population of cells. METHODS We used a double transgenic model in which mice express CD8 T cells specific for a prostate/prostate cancer antigen to study the response of CD8 T cells to evolving autochronous prostate tumors in TRAMP mice. CD8 T cells were analyzed for functionality by measuring IFN-Î production via flow cytometry and via an in vivo CTL killing assay. In addition, pathological scoring of the prostates of the double transgenic mice was compared to scoring of tumor burden prostates of ProTRAMP mice. Results: Tumor-specific CD8 T cells were not grossly deleted in these animals, but evidenced a clearly non-functional phenotype. Interestingly, full lytic function was rapidly recovered upon removal from tumor-bearing mice. Conclusions: These data indicate a role for continuous antigen exposure in the maintenance of tumor-specific CD8 T-cell tolerance to prostate cancer.

Original languageEnglish (US)
Pages (from-to)514-522
Number of pages9
Issue number5
StatePublished - Apr 2012


  • Clone 4
  • anergy
  • hemagglutinin
  • tolerance

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of 'Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model'. Together they form a unique fingerprint.

Cite this